Several studies have demonstrated that tumor microenvironment-derived metabolites can induce the resistance of tumor cells towards targeted agents.25–27 To explore how FAK inhibition might change the metabolic profile of CAFs, we performed an untargeted LC-MS-based metabolomic analysis in CAFs #1 treated with defactinib (10 μM). Here, PTK2 is linked to neoplasm.